Competition and Markets Authority
U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.
The U.K.’s competition authority claims Merck's Remicade discounts, aimed at defending against biosimilar competition, “broke competition law."
Officials in the U.K. are taking issue with huge price hikes, now targeting Actavis for a 12,000% increase.
The U.K. government slapped Pfizer with a record price-gouging fine for triggering a 2,600% price increase on an epilepsy drug.